Hutchmed/$HCM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Hutchmed

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Ticker

$HCM
Primary listing

Industry

Pharmaceuticals

Headquarters

Hong Kong, Hong Kong

Employees

1,811

ISIN

US44842L1035

Hutchmed Metrics

BasicAdvanced
$2.7B
399.26
$0.04
0.75
-

Bulls say / Bears say

HUTCHMED reported a net income of $100.8 million in fiscal 2023, a significant turnaround from the previous year's net loss of $360.8 million, driven by a 97% increase in revenue to $838 million. (markets.businessinsider.com)
The company's oncology product revenue grew by 59% in the first half of 2024, contributing to a total Oncology/Immunology consolidated revenue of $168.7 million, indicating strong commercial progress. (investor.wedbush.com)
Analysts have set a mean price target of $25.75 for HUTCHMED, suggesting a potential upside of 68.3% from the current trading price. (nasdaq.com)
HSBC downgraded HUTCHMED's stock from a 'buy' rating to a 'hold' rating on May 13, 2025, indicating potential concerns about the company's future performance. (defenseworld.net)
The average one-year price target for HUTCHMED has been revised down by 10.68% to $16.92, reflecting a more cautious outlook from analysts. (fintel.io)
Despite recent profitability, the company's stock price has experienced volatility, with a 52-week range between $11.51 and $21.50, which may concern risk-averse investors. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HCM

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs